Markets Stifel cuts Supernus Pharma to hold; PT to $23 from $55 Stifel downgraded Supernus Pharmaceuticals (NASDAQ:SUPN) to “hold” from “buy” and slashed its price target to $23 from $55 after a Phase 3 miss with drug candidate, SPN-810, for the treatment of impulsive aggression in... November 7, 2019